Synapse - Robert Motzer

Search Within

Robert Motzer

Results (1243)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Journal Article

Deutsch, J. S.; Lipson, E. J.; Danilova, L.; Topalian, S. L.; Jedrych, J.; Baraban, E.; Ged, Y.; Singla, N.; Choueiri, T. K.; Gupta, S.; more...
Cell Reports Medicine (2023)

Fulltext@MSK | Save

Association of body mass index with the safety profile of nivolumab with or without ipilimumab

Journal Article

McQuade, J. L.; Hammers, H.; Furberg, H.; Engert, A.; André, T.; Blumenschein, G. Jr; Tannir, N.; Baron, A.; Larkin, J.; El-Khoueiry, A.; more...
JAMA Oncology (2023)

Fulltext@MSK | Save

Matched molecular profiling of cell-free DNA and tumor tissue in patients with advanced clear cell renal cell carcinoma

Journal Article

Kotecha, R. R.; Gedvilaite, E.; Ptashkin, R.; Knezevic, A.; Murray, S.; Johnson, I.; Shapnik, N.; Feldman, D. R.; Carlo, M. I.; Shah, N. J.; more...
JCO Precision Oncology (2022)

Fulltext@MSK | Save

A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors

Meeting Abstract

McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214

Meeting Abstract

Gupta, S.; Han, C.; Dwivedi, B.; Li, J.; Karsdal, M.; Motzer, R.; Willumsen, N.; McDermott, D.; Choueiri, T.
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas

Journal Article

Yoo, A.; Tang, C.; Zucker, M.; Fitzgerald, K.; DiNatale, R. G.; Rappold, P. M.; Weiss, K.; Freeman, B.; Lee, C. H.; Schultz, N.; more...
European Urology Focus (2022)

Fulltext@MSK | Save

Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Meeting Abstract

Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

Meeting Abstract

Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

Meeting Abstract

Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U. F. F.; Buchler, T.; Basappa, N. S.; Vidal, M. J. M.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)

Meeting Abstract

Cella, D.; Porta, C. G.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Rodriguez, C. S.; Choueiri, T. K.; Motzer, R. J.
Annals of Oncology (2022)

Fulltext@MSK | Save